Search Results for "Gilenya 2012 May"
Matching Channels
Macitentan (Opsumit®) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target to develop an ERA optimized for efficacy and safet...
ATX-MS-1467 for patients with multiple sclerosis (MS)
ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the...
According to the American Brain Tumor Association, just over 24,000 patients will be diagnosed with a primary malignant brain tumour during 2012 in the US alone. Some 80% of primary malignant brain...
Coronavirus were first identified in the 1960s, and were named after the crown-like projections on the surface of the virus. They cause respiratory infections in both humans and animals. Coronavir...
Sequencing platforms in diagnostic laboratories may aid both patient management by detecting resistance associated mutations, and public health measures, by determining phylogenetic relationships be...
Matching News
New analysis shows Novartis drug Gilenya significantly reduced rate of brain volume loss across ...
Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS1 Gilenya is the first o...
Novartis Confirms Growing Gilenya Clinical & Real-world Experience
BASEL (dpa-AFX) - Swiss pharmaceutical giant Novartis AG (NVS) confirmed growing Gilenya clinical and real-world experience, as number of patients treated increases to over 63,000. Gilenya is the ...
Novartis drug Gilenya shows long-term efficacy and safety according to new data from extension ...
Data from single-arm extension of head-to-head TRANSFORMS study show sustained reduction in relapses and rate of brain volume loss in patients on continuous Gilenya treatment for up to 4.5 years...
The U.S. Food and Drug Administration (FDA) has completed its evaluation of a report of a patient who died after the first dose of multiple sclerosis drug Gilenya (fingolimod). The agency also has ev...
Epstein bullish on Gilenya after strong Q2
David Epstein, head of Novartis Pharmaceuticals, urged analysts to take a rosier view of the ex-US prospects for its multiple sclerosis drug Gilenya (fingolimod) after the product turned in healthy g...
FDA Approves Clinical Trial of TDI-132 (Gilenya) in ALS Patients
CAMBRIDGE, Mass., Feb. 11, 2013 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) announced today that it has received FDA approval to conduct a clinical trial of TDI-132 (aka...
EAST HANOVER, N.J., March 21, 2013 /PRNewswire/ -- New data presented at the 65th annual meeting of the American Academy of Neurology (AAN) show Gilenya® (fingolimod), the first oral disease modif...
Novartis Says MS Drug Gilenya Consistently Reduces Brain Volume Loss
BASEL (dpa-AFX) - Swiss drug giant Novartis AG (NVS) on Tuesday confirmed that its multiple sclerosis drug Gilenya (fingolimod) has shown consistent and sustained efficacy, with the number of pati...
Matching PubMed Articles
Abstract Objective To assess the costs of oral treatment with Gilenya® * (fingolimod) compared to intravenous infusion of Tysabri® † (natalizumab) in patients with relapsing-remitting multiple scl...
Nefrologia 2012;32(6):838-9. doi: 10.3265/Nefrologia.pre2012.Oct.11783. Reply to: Del Pozo et al. Comment on Nefrologia 2012;32(6):837. Nefrologia 2012; 32(4):419-26.
ISS/SIC Donations January 2012 Through June 2012.
Nefrologia 2012;32(6):835-7. doi: 10.3265/Nefrologia.pre2012.Oct.11731. Reply to: Serra Tarragon. Comment on Nefrologia 2012;32(6):835. Nefrologia 2012; 32(4):419-26.
Abstracts of the 2012 Vascular Annual Meeting. National Harbor, Maryland, USA. June 7-9, 2012.
